{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:36:28Z","timestamp":1791567388404,"version":"4.3.4"},"reference-count":21,"publisher":"American Society of Hematology","issue":"8","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Vaso-occlusive episodes (VOC) or pain crises are the most common indications for hematopoietic cell transplantation (HCT) for sickle cell disease (SCD). Elimination of pain crisis after HCT is an important patient-centered outcome and may improve understanding of the natural history of pain syndromes in SCD. We examined deidentified records of 763 patients followed-up for a median of 36.7\u00a0months (range, 0.3-168.6\u00a0months), with 69.6% patient's age &amp;lt;18 years at HCT, 83.3% patient's Karnofsky-Lansky performance score (KPS) \u226590, overall survival 92.9%, event-free survival 72.4%, graft failure (GF) 22.4%, AGVHD 21.4%, CGVHD 27%, and pain crisis 8.65%. On unadjusted logistic regression, increased risk of pain crisis after HCT was observed in patient's aged &amp;gt;10 years at HCT\u00a0(range, 11-17 years; OR, 9.43; 95% CI, 3.20-27.79; P\u00a0&amp;lt;\u00a0.0001), in age \u226518 years (OR, 16.62; 95%\u00a0CI, 5.85-47.16; P\u00a0&amp;lt; .0001), in those with history of pain crisis 2 years before HCT (OR, 13.16; 95%\u00a0CI, 4.08-42.42; P\u00a0&amp;lt; .0001), alternate donors (haploidentical [OR, 4.80; 95%\u00a0CI, 2.48-9.31; P\u00a0&amp;lt; .0001], unrelated matched [OR, 2.71; 95%\u00a0CI, 1.23-5.97; P\u00a0= .0132], and mismatched unrelated [OR, 3.19; 95%\u00a0CI, 1.44-7.05; P\u00a0= .0041], and those with GF (n\u00a0= 41 [5.37%]; OR, 7.15; 95%\u00a0CI, 4.20-12.18; P\u00a0&amp;lt;\u00a0.0001). Pain crisis was less frequent with KPS of \u226590 (OR, 0.31; 95%\u00a0CI, 0.18-0.55; P\u00a0&amp;lt;\u00a0.0001). Multivariable logistic regression models confirmed age at HCT, KPS, graft type, donor type, history of VOC 2 years before HCT, and GF as independent predictors of pain crisis after HCT and generated predictive models and nomograms for pain crisis after HCT for SCD, which can support shared decision making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023010749","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T15:04:31Z","timestamp":1707318271000},"page":"1908-1919","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3242-0037","authenticated-orcid":false,"given":"Lakshmanan","family":"Krishnamurti","sequence":"first","affiliation":[{"name":"1Section of Pediatric Hematology-Oncology and Stem Cell Transplantation, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingchen","family":"Liang","sequence":"additional","affiliation":[{"name":"2Yale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2988-4590","authenticated-orcid":false,"given":"Zili","family":"He","sequence":"additional","affiliation":[{"name":"2Yale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6873-8026","authenticated-orcid":false,"given":"Yanhong","family":"Deng","sequence":"additional","affiliation":[{"name":"2Yale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineetha R.","family":"Nallagatla","sequence":"additional","affiliation":[{"name":"1Section of Pediatric Hematology-Oncology and Stem Cell Transplantation, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohaum","family":"Hamidi","sequence":"additional","affiliation":[{"name":"3Yale New Haven Children's Hospital, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7097-0657","authenticated-orcid":false,"given":"Aron","family":"Flagg","sequence":"additional","affiliation":[{"name":"1Section of Pediatric Hematology-Oncology and Stem Cell Transplantation, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niketa","family":"Shah","sequence":"additional","affiliation":[{"name":"1Section of Pediatric Hematology-Oncology and Stem Cell Transplantation, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,4,11]]},"reference":[{"issue":"12","key":"2024042313153014400_bib1","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1056\/NEJM198409203111207","article-title":"Bone-marrow transplantation in a patient with sickle-cell anemia","volume":"311","author":"Johnson","year":"1984","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2024042313153014400_bib2","first-page":"310","article-title":"Collaborative multicenter investigation of marrow transplantation for sickle cell disease: current results and future directions","volume":"3","author":"Walters","year":"1997","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2024042313153014400_bib3","doi-asserted-by":"crossref","first-page":"S285","DOI":"10.1016\/S2666-6367(23)00447-5","article-title":"Main reasons for performing hematopoietic cell transplantation in patients with sickle cell disease: evolution over the last three decades","volume":"29","author":"Flagg","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"2024042313153014400_bib4","doi-asserted-by":"crossref","first-page":"e28749","DOI":"10.1002\/pbc.28749","article-title":"Primary caregiver decision-making in hematopoietic cell transplantation and gene therapy for sickle cell disease","volume":"68","author":"Sinha","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2024042313153014400_bib5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ejh.13430","article-title":"The vaso-occlusive pain crisis in sickle cell disease: definition, pathophysiology, and management","volume":"105","author":"Darbari","year":"2020","journal-title":"Eur J Haematol"},{"issue":"3","key":"2024042313153014400_bib6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.bbmt.2015.12.002","article-title":"A\u00a0standard nonmyeloablative transplantation regimen for adults with sickle cell disease: are we there yet?","volume":"22","author":"Hsieh","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2024042313153014400_bib7","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.15169","article-title":"Pain and opioid use after reversal of sickle cell disease following HLA-matched sibling haematopoietic stem cell transplant","volume":"184","author":"Darbari","year":"2019","journal-title":"Br J Haematol"},{"issue":"3","key":"2024042313153014400_bib8","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1111\/bjh.16999","article-title":"Chronic opioid use can be reduced or discontinued after haematopoietic stem cell transplantation for sickle cell disease","volume":"191","author":"Han","year":"2020","journal-title":"Br J Haematol"},{"issue":"4","key":"2024042313153014400_bib9","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ajh.25401","article-title":"Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study","volume":"94","author":"Krishnamurti","year":"2019","journal-title":"Am J Hematol"},{"issue":"3","key":"2024042313153014400_bib10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2029392","article-title":"Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease","volume":"384","author":"Esrick","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024042313153014400_bib11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of lentiglobin for sickle cell disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024042313153014400_bib12","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024042313153014400_bib13","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D'Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2024042313153014400_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2014.7192","article-title":"Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype","volume":"312","author":"Hsieh","year":"2014","journal-title":"JAMA"},{"issue":"2","key":"2024042313153014400_bib15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/bloodadvances.2022008137","article-title":"Reduction in vaso-occlusive events following stem cell transplantation in patients with sickle cell disease","volume":"7","author":"Leonard","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"2024042313153014400_bib16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/ejh.12340","article-title":"Thinking beyond sickling to better understand pain in sickle cell disease","volume":"93","author":"Darbari","year":"2014","journal-title":"Eur J Haematol"},{"issue":"5","key":"2024042313153014400_bib17","first-page":"617","article-title":"An evaluation of central sensitization in patients with sickle cell disease","volume":"17","author":"Campbell","year":"2016","journal-title":"J\u00a0Pain"},{"issue":"1 Suppl 1","key":"2024042313153014400_bib18","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.amepre.2016.02.012","article-title":"Chronic opioid therapy and central sensitization in sickle cell disease","volume":"51","author":"Carroll","year":"2016","journal-title":"Am J Prev Med"},{"issue":"2","key":"2024042313153014400_bib19","first-page":"183","article-title":"Understanding pain and improving management of sickle cell disease: the PiSCES study","volume":"97","author":"Smith","year":"2005","journal-title":"J\u00a0Natl Med Assoc"},{"issue":"4","key":"2024042313153014400_bib20","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41409-022-01584-y","article-title":"Significant improvement of child physical and emotional functioning after familial haploidentical stem cell transplant","volume":"57","author":"Parsons","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2024042313153014400_bib21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.bbmt.2015.08.036","article-title":"Nonmyeloablative stem cell transplantation with alemtuzumab\/low-dose irradiation to cure and improve the quality of life of adults with sickle cell disease","volume":"22","author":"Saraf","year":"2016","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/8\/1908\/2222817\/blooda_adv-2023-010749-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/8\/1908\/2222817\/blooda_adv-2023-010749-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T09:15:47Z","timestamp":1713863747000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/8\/1908\/514840\/Incidence-and-risk-factors-of-pain-crisis-after"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,11]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,4,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010749","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,11]]}}}